Status:
COMPLETED
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
Lead Sponsor:
Pfizer
Conditions:
Solid Tumors
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors
Eligibility Criteria
Inclusion
- Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists
- Patient has good performance status (ECOG 0 or 1)
Exclusion
- Prior treatment with either SU011248 or capecitabine.
- Hypertension that cannot be controlled by medications
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00618124
Start Date
May 1 2005
End Date
July 1 2008
Last Update
May 3 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46202
2
Pfizer Investigational Site
Albuqurque, New Mexico, United States, 87131
3
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203